Study guide
8.2 MNT for Diabetes Mellitus and Endocrine Disorders
Nutritionist-Dietitian Licensure Examination NDLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Licensure Law, Ethics, and the Clinical Nutritionist-Dietitian
1.1 NDLE Format, Scoring Rules, and RA 10862 Licensure Requirements 1.2 Scope of Practice, Professional Ethics, and Discipline under RA 10862 1.3 Role of the Clinical Nutritionist-Dietitian, Diet Orders, and Standard Hospital Diets
2 Chapter 2: Anatomy and Physiology for Nutrition I
2.1 Cells, Tissues, Membranes, and the Immune and Lymphatic Systems 2.2 The Digestive System: Organs, Enzymes, GI Hormones, and the Liver 2.3 Endocrine and Nervous System Regulation of Metabolism and Appetite
3 Chapter 3: Anatomy and Physiology II, Energy, and Carbohydrate Metabolism
3.1 Cardiovascular, Respiratory, Renal, Musculoskeletal, and Reproductive Systems 3.2 Energy Metabolism and Energy Expenditure Calculations 3.3 Carbohydrate Chemistry, Digestion, and Glycemic Pathways
4 Chapter 4: Protein, Lipid, Mineral, and Fluid Biochemistry
4.1 Protein Chemistry, Amino Acid Metabolism, and Nitrogen Balance 4.2 Lipid Metabolism, Lipoproteins, and Cardiovascular Biomarkers 4.3 Minerals, Water, Electrolytes, and Acid-Base Balance
5 Chapter 5: Basic Nutrition: Vitamins, Minerals, and the PDRI
5.1 Vitamin Biochemistry: Coenzyme Functions and Deficiency Syndromes 5.2 Vitamins and Minerals: PDRI Values, Food Sources, Bioavailability, Stability, and Toxicity 5.3 Philippine Dietary Reference Intakes (PDRI 2015), Pinggang Pinoy, and Dietary Guidelines
6 Chapter 6: Diet Computation and Clinical Nutrition Assessment
6.1 Food Exchange Lists, Meal Plan Computation, Food Labels, and Nutrient Density 6.2 Computing Desirable Body Weight, Total Energy Requirement, and the Diet Prescription 6.3 ABCD Methods of Clinical Nutrition Assessment
7 Chapter 7: Nutrition Diagnosis, Life-Stage Assessment, and Laboratory Data
7.1 Nutrition Diagnosis, PES Statements, and Medical Record Documentation 7.2 Pediatric, Obstetric, and Geriatric Clinical Nutritional Assessment 7.3 Interpreting Biochemical and Laboratory Data in Nutrition Assessment
8 Chapter 8: Drug-Nutrient Interactions, Diabetes, and Weight Disorders
8.1 Drug-Nutrient Interactions and Nutrient Depletion 8.2 MNT for Diabetes Mellitus and Endocrine Disorders 8.3 MNT for Overweight, Obesity, and Underweight
9 Chapter 9: MNT for Cardiovascular, Renal, and Gastrointestinal Disease
9.1 MNT for Cardiovascular Disease, Hypertension, and Dyslipidemia 9.2 MNT for Renal Diseases (AKI, CKD Stages 1-5, Dialysis, and Nephrotic Syndrome) 9.3 MNT for Disorders of the Gastrointestinal Tract
10 Chapter 10: MNT for Liver, Infectious, Respiratory, Allergic, and Neurologic Conditions
10.1 MNT for Liver, Gallbladder, and Pancreatic Disorders 10.2 MNT for Fevers, Infections, Diarrheal Disease, and Respiratory Disorders 10.3 MNT for Food Allergy and Intolerance, Skin, Rheumatic, Musculoskeletal, and Neurologic Disorders
11 Chapter 11: Critical Illness, Oncology, HIV, and Protein-Energy Malnutrition
11.1 MNT in Critical Illness, Sepsis, Trauma, and Burns 11.2 MNT in Oncology: Cancer Cachexia and Treatment Side Effects 11.3 MNT for HIV/AIDS and for Protein-Energy Malnutrition in Children and Adults
12 Chapter 12: Metabolic Disorders, Dysphagia, and Enteral Nutrition
12.1 MNT for Inborn Errors of Metabolism and Eating Disorders 12.2 Dysphagia, IDDSI Texture-Modified Diets, and Adaptive Feeding 12.3 Enteral Nutrition: Indications, Formula Selection, Access Routes, and Complications
13 Chapter 13: Parenteral Nutrition, Refeeding, and Nutrition Counseling
13.1 Parenteral Nutrition: Indications, Access, Substrates, and Compounding 13.2 Refeeding Syndrome and Complications of Parenteral Nutrition 13.3 Nutrition Counseling and Behavior Change Theories
14 Chapter 14: Nutrition Updates: Supplements, Diet Trends, and Sports Nutrition
14.1 Dietary Supplements, Herbal Medicines, and Functional Foods 14.2 Vegetarian Diets, Protein Complementation, and Popular Diet Trends 14.3 Sports Nutrition and Workplace Wellness Programs
15 Chapter 15: Community Nutrition and Population Assessment
15.1 Community Nutrition Principles, the ND's Roles, and the Philippine Health Delivery System 15.2 Nutritional Epidemiology and Health Status Indicators in the Philippines 15.3 Assessment of Community Nutritional Status and Operation Timbang Plus (OPT+)
16 Chapter 16: Dietary Surveys, Nutrition Research, and Surveillance
16.1 Food Consumption Surveys, Biochemical Tests in Surveys, and Clinical Signs of Deficiency 16.2 Food and Nutrition Research Methods, Sampling, Sample Size, and Research Ethics 16.3 National Nutrition Surveys, Demographic Data, and Designing a Nutrition Surveillance System
17 Chapter 17: Nutrition Education and Program Evaluation
17.1 Nutrition Education: Definition, Principles of Learning, Methods, and Teaching Aids 17.2 Designing a Nutrition Education Program and Measuring Customer Satisfaction 17.3 Program Planning Cycle, SMART Objectives, and Types of Evaluation
18 Chapter 18: Program Planning, Interventions, and Food Security
18.1 Nutrition Program Planning: Needs, Priorities, Constraints, Goals, and Using Evaluation Results 18.2 Nutrition Interventions and Programs for Specific Population Groups 18.3 Food and Nutrition Security, Dietary Diversity, and Vulnerable Populations
19 Chapter 19: Nutrition Governance, Networking, and Program History
19.1 National Nutrition Council (NNC) Structure and Philippine Plan of Action for Nutrition (PPAN) 19.2 Nutrition Agencies, Networking, Community Linkages, Teamwork, and Nutrition Legislation 19.3 Development of Philippine Nutrition Programs and the Country's Nutrition Problems
20 Chapter 20: Fortification, Feeding, and First 1,000 Days Laws
20.1 Food Fortification (RA 8976), Salt Iodization (RA 8172), and the 2024 Salt Industry Law 20.2 Supplementary Feeding Programs (RA 11037) and DSWD/DepEd Interventions 20.3 First 1,000 Days Law (RA 11148) and Maternal-Child Interventions
21 Chapter 21: Nutrition in the Life Cycle I
21.1 Infant and Young Child Feeding (IYCF), Philippine Milk Code (EO 51), and RA 10028 21.2 Nutrition in Pregnancy and Lactation: Physiology, Needs, Meal Patterns, and Problems 21.3 Nutrition from Infancy to School Age: Growth, Feeding Patterns, Problems, and School Programs
22 Chapter 22: Nutrition in the Life Cycle II
22.1 Nutrition for Adolescents and Adults: Growth Spurt, Risk Factors, and NCD Prevention 22.2 Nutrition for Older Adults: Aging Changes, Needs, Problems, and Senior Citizen Programs
23 Chapter 23: Food Science and Plant Foods
23.1 Chemistry of Starches, Proteins, Lipids, and Emulsions in Cooking 23.2 Food Pigments, Flavor Chemistry, and Browning Reactions (Maillard & Enzymatic) 23.3 Fruits, Vegetables, and Legumes: Classification, Market Forms, Quality, Storage, and Cookery
24 Chapter 24: Animal Foods, Cereals and Baking, and Cooking Methods
24.1 Meat, Poultry, Fish, Eggs, and Milk: Structure, Quality, Storage, and Cookery 24.2 Cereals, Flour Mixtures and Baking, Sugar Cookery, Fats and Oils, and Beverages 24.3 Heat Transfer, Dry-Heat and Moist-Heat Cooking Methods, and Filipino Cooking Techniques
25 Chapter 25: Culinary Skills, Family Meal Planning, and Food Quality
25.1 Culinary Vocabulary, Knife Cuts, Basic Sauces, and Accurate Measurement 25.2 Meal Planning for the Family, Food Budgeting, and Recipe Development 25.3 Sensory Evaluation, Objective Food Tests, and Quality Assurance in Food Production
26 Chapter 26: Food Microbiology, Preservation, and Food Law
26.1 Foodborne Pathogens, Microbial Kinetics, and FAT TOM Parameters 26.2 Food Preservation Methods, Thermal Processing, and Packaging 26.3 Philippine Food Laws, Regulatory Agencies, and Food Labeling
27 Chapter 27: Sanitation, HACCP, Waste, and Workplace Safety
27.1 Sanitation Standard Operating Procedures (SSOP) and Good Manufacturing Practices (GMP) 27.2 HACCP Principles and Critical Control Point Management in Food Service 27.3 Waste Management, Pest Control Regulation, and Occupational Safety in Food Service
28 Chapter 28: Food Service Systems, Production Planning, and Menus
28.1 Types of Food Service Delivery Systems (Conventional, Ready-Prepared, Commissary, Assembly) 28.2 Forecasting, Production Planning, and Quantity Food Production Techniques 28.3 Institutional Menu Planning, Modified Diets, and Recipe Standardization
29 Chapter 29: Distribution, Purchasing, and Storage
29.1 Food Distribution and Service Systems in Hospitals and Other Institutions 29.2 Food Purchasing Methods, Specifications, and Receiving 29.3 Storage Management, Inventory Control, and Valuation
30 Chapter 30: Cost Control, Financial Management, and Facility Layout
30.1 Food Cost Accounting, Yield Testing, and Portion Control Formulas 30.2 Menu Pricing Models, Break-Even Analysis, and Financial Statements 30.3 Food Service Facility Layout, Equipment Selection, and Workflow Ergonomics
31 Chapter 31: Equipment, Management, and Human Resources
31.1 Food Service Equipment: Selection, Capacity, Life-Cycle Cost, Depreciation, and Maintenance 31.2 Management Functions, Theories, Leadership Styles, and Managing Change in Food Service 31.3 Human Resource Management: Job Design, Recruitment, Training, Appraisal, and Discipline
32 Chapter 32: Labor Law, Permits, and Food Service Marketing
32.1 Philippine Labor Laws and Business Permits for Food Service Operations 32.2 Food Service Marketing, Menu Engineering, and Sustainable Food Service
8.2 MNT for Diabetes Mellitus and Endocrine Disorders
Key Takeaways Explain This Topic AI
Clinical diagnosis of diabetes mellitus requires a fasting blood glucose ≥ 126 mg/dL \ge 126\text{ mg/dL} ≥ 126 mg/dL , a 2-hour 75g OGTT ≥ 200 mg/dL \ge 200\text{ mg/dL} ≥ 200 mg/dL , an HbA1c ≥ 6.5 % \text{HbA1c} \ge 6.5\% HbA1c ≥ 6.5% , or a random blood glucose ≥ 200 mg/dL \ge 200\text{ mg/dL} ≥ 200 mg/dL with classic osmotic symptoms.
Gestational diabetes mellitus (GDM) is diagnosed via a one-step 75g OGTT at 24–28 weeks using IADPSG criteria (fasting ≥ 92 mg/dL \ge 92\text{ mg/dL} ≥ 92 mg/dL , 1-hr ≥ 180 mg/dL \ge 180\text{ mg/dL} ≥ 180 mg/dL , 2-hr ≥ 153 mg/dL \ge 153\text{ mg/dL} ≥ 153 mg/dL ), mandating ≥ 175 g/day \ge 175\text{ g/day} ≥ 175 g/day of carbohydrate to prevent ketonemia.
Advanced carbohydrate counting employs the 500 Rule for the Insulin-to-Carbohydrate Ratio ( ICR = 500 / TDD \text{ICR} = 500 / \text{TDD} ICR = 500/ TDD ) and the 1800 Rule for the Insulin Sensitivity Factor ( ISF = 1800 / TDD \text{ISF} = 1800 / \text{TDD} ISF = 1800/ TDD ), while the Food Exchange Lists for Filipinos (FNRI) standardize exchange portioning.
Hypoglycemia ( < 70 mg/dL < 70\text{ mg/dL} < 70 mg/dL ) is corrected via the Rule of 15; differentiation of fasting morning hyperglycemia relies on 3:00 AM blood glucose (hypoglycemic rebound in Somogyi effect vs. euglycemic/hyperglycemic cortisol surge in Dawn phenomenon).
In endocrine disorders, hyperthyroidism requires hypercaloric repletion ( 35 – 40 kcal/kg 35–40\text{ kcal/kg} 35–40 kcal/kg ), hypothyroidism mandates strict separation of levothyroxine from dietary calcium, iron, and fiber, and PCOS targets insulin resistance through a low-glycemic, anti-inflammatory pattern.
Last updated: October 2026
Diabetes mellitus represents a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia is directly associated with long-term damage, dysfunction, and failure of various organ systems, especially the eyes, kidneys, nerves, heart, and blood vessels. In clinical dietetics, Medical Nutrition Therapy (MNT) is an essential component of comprehensive diabetes management, capable of reducing glycated hemoglobin ( HbA1c \text{HbA1c} HbA1c ) by 1.0% to 2.0% when delivered by a licensed Registered Nutritionist-Dietitian (RND).
Pathophysiology and Classification of Diabetes Mellitus
Diabetes is classified into four clinical categories based on underlying etiology and pathophysiological mechanisms:
1. Type 1 Diabetes Mellitus (T1DM)
Etiology: Cellular-mediated autoimmune destruction of pancreatic β \beta β -cells within the islets of Langerhans, mediated by autoantibodies against glutamic acid decarboxylase (anti-GAD65), islet cell antibodies (ICA512/IA-2), and insulin autoantibodies (IAA).
Pathophysiology: Absolute insulin deficiency. Without exogenous insulin administration, unrestrained lipolysis and hepatic ketogenesis occur, precipitating life-threatening Diabetic Ketoacidosis (DKA) .
Clinical Presentation: Rapid onset in children or young adults characterized by the classic osmotic triad: polyuria, polydipsia, and polyphagia, accompanied by dramatic unintentional weight loss, ketonuria, metabolic acidosis (anion gap > 12 mEq/L > 12\text{ mEq/L} > 12 mEq/L ), and deep, rapid Kussmaul respirations.
2. Type 2 Diabetes Mellitus (T2DM)
Etiology: Progressive loss of adequate β \beta β -cell insulin secretion frequently on the background of peripheral insulin resistance (skeletal muscle, adipose tissue, and liver).
Pathophysiology: Characterized by hyperinsulinemia during early stages, which gradually fails as β \beta β -cells undergo secretory exhaustion and glucolipotoxicity. Hepatic gluconeogenesis proceeds unchecked, and skeletal muscle glucose uptake via GLUT-4 transporters is severely blunted.
Acute Complication: Prone to Hyperglycemic Hyperosmolar State (HHS) rather than DKA, characterized by profound hyperglycemia ( > 600 mg/dL > 600\text{ mg/dL} > 600 mg/dL ), serum hyperosmolality ( > 320 mOsm/kg > 320\text{ mOsm/kg} > 320 mOsm/kg ), and severe dehydration without significant ketoacidosis, due to residual endogenous insulin sufficient to suppress lipolysis.
3. Gestational Diabetes Mellitus (GDM)
Etiology: Hyperglycemia recognized during the second or third trimester of pregnancy that is not clearly overt preexisting type 1 or type 2 diabetes.
Pathophysiology: Human placental lactogen (hPL), progesterone, cortisol, and prolactin reach peak circulating levels between 24 and 28 weeks of gestation, producing physiological insulin resistance. When maternal pancreatic β \beta β -cells cannot mount a compensatory 2- to 3-fold increase in insulin secretion, maternal and fetal hyperglycemia ensue.
Diagnostic Protocol (One-Step 75g OGTT): Endorsed by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and the American Diabetes Association (ADA). Administered in the morning after an 8- to 14-hour overnight fast at 24–28 weeks of gestation:
Fasting Plasma Glucose (FPG) ≥ 92 mg/dL ( 5.1 mmol/L ) \text{Fasting Plasma Glucose (FPG)} \ge 92\text{ mg/dL } (5.1\text{ mmol/L}) Fasting Plasma Glucose (FPG) ≥ 92 mg/dL ( 5.1 mmol/L ) 1-Hour Plasma Glucose ≥ 180 mg/dL ( 10.0 mmol/L ) \text{1-Hour Plasma Glucose} \ge 180\text{ mg/dL } (10.0\text{ mmol/L}) 1-Hour Plasma Glucose ≥ 180 mg/dL ( 10.0 mmol/L ) 2-Hour Plasma Glucose ≥ 153 mg/dL ( 8.5 mmol/L ) \text{2-Hour Plasma Glucose} \ge 153\text{ mg/dL } (8.5\text{ mmol/L}) 2-Hour Plasma Glucose ≥ 153 mg/dL ( 8.5 mmol/L )
Diagnostic Criterion: Meeting or exceeding any single threshold confirms the diagnosis of GDM.
Important
Glycemic targets in GDM are substantially tighter than in non-pregnant adults to prevent fetal macrosomia, neonatal hypoglycemia, and shoulder dystocia: Fasting < 95 mg/dL < 95\text{ mg/dL} < 95 mg/dL ( 5.3 mmol/L 5.3\text{ mmol/L} 5.3 mmol/L ), 1-hour postprandial < 140 mg/dL < 140\text{ mg/dL} < 140 mg/dL ( 7.8 mmol/L 7.8\text{ mmol/L} 7.8 mmol/L ), and 2-hour postprandial < 120 mg/dL < 120\text{ mg/dL} < 120 mg/dL ( 6.7 mmol/L 6.7\text{ mmol/L} 6.7 mmol/L ). Minimum dietary carbohydrate must never fall below 175 g/day 175\text{ g/day} 175 g/day to prevent maternal ketonemia, which impairs fetal neurodevelopment.
4. Specific Types Due to Other Causes
Monogenic diabetes syndromes (MODY, neonatal diabetes), diseases of the exocrine pancreas (cystic fibrosis, chronic pancreatitis / Type 3c diabetes), and drug- or chemical-induced diabetes (glucocorticoid therapy, immunosuppression following organ transplantation, antiretroviral regimens).
Diagnostic Criteria for Prediabetes and Overt Diabetes Mellitus
Standard diagnostic cut-offs from the American Diabetes Association Standards of Care, also used in Philippine clinical practice, are outlined below:
Diagnostic Test Normal Prediabetes (Impaired Fasting / Impaired Tolerance) Diabetes Mellitus (Diagnostic Threshold)
Fasting Blood Glucose (FBG) < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL ( 5.6 mmol/L 5.6\text{ mmol/L} 5.6 mmol/L ) 100 − 125 mg/dL 100 - 125\text{ mg/dL} 100 − 125 mg/dL ( 5.6 − 6.9 mmol/L 5.6 - 6.9\text{ mmol/L} 5.6 − 6.9 mmol/L ) (Impaired Fasting Glucose, IFG) ≥ 126 mg/dL \ge 126\text{ mg/dL} ≥ 126 mg/dL ( 7.0 mmol/L 7.0\text{ mmol/L} 7.0 mmol/L )*
2-Hour 75g OGTT < 140 mg/dL < 140\text{ mg/dL} < 140 mg/dL ( 7.8 mmol/L 7.8\text{ mmol/L} 7.8 mmol/L ) 140 − 199 mg/dL 140 - 199\text{ mg/dL} 140 − 199 mg/dL ( 7.8 − 11.0 mmol/L 7.8 - 11.0\text{ mmol/L} 7.8 − 11.0 mmol/L ) (Impaired Glucose Tolerance, IGT) ≥ 200 mg/dL \ge 200\text{ mg/dL} ≥ 200 mg/dL ( 11.1 mmol/L 11.1\text{ mmol/L} 11.1 mmol/L )*
Glycated Hemoglobin ( HbA1c \text{HbA1c} HbA1c ) < 5.7 % < 5.7\% < 5.7% 5.7 − 6.4 % 5.7 - 6.4\% 5.7 − 6.4% ≥ 6.5 % \ge 6.5\% ≥ 6.5% ( 48 mmol/mol 48\text{ mmol/mol} 48 mmol/mol )*
Random Plasma Glucose (RPG) — — ≥ 200 mg/dL \ge 200\text{ mg/dL} ≥ 200 mg/dL with classic symptoms of hyperglycemia
In the absence of unequivocal symptomatic hyperglycemia (polyuria, polydipsia, polyphagia, unexplained weight loss), diagnosis requires two abnormal test results from the same sample or two separate test samples.
Medical Nutrition Therapy Goals and Macronutrient Distribution
The overarching goals of MNT in diabetes are to attain individualized glycemic, blood pressure, and lipid targets while preventing or decelerating microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary artery disease, peripheral arterial disease, stroke) complications.
Clinical Therapeutic Targets for Non-Pregnant Adults
Glycemic Targets: HbA1c < 7.0 % \text{HbA1c} < 7.0\% HbA1c < 7.0% ( < 53 mmol/mol < 53\text{ mmol/mol} < 53 mmol/mol ) for most non-pregnant adults; preprandial capillary plasma glucose 80 − 130 mg/dL 80 - 130\text{ mg/dL} 80 − 130 mg/dL ( 4.4 − 7.2 mmol/L 4.4 - 7.2\text{ mmol/L} 4.4 − 7.2 mmol/L ); peak postprandial capillary plasma glucose < 180 mg/dL < 180\text{ mg/dL} < 180 mg/dL ( < 10.0 mmol/L < 10.0\text{ mmol/L} < 10.0 mmol/L ).
Blood Pressure: < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg .
Lipid Targets: LDL-C < 100 mg/dL \text{LDL-C} < 100\text{ mg/dL} LDL-C < 100 mg/dL (or < 70 mg/dL < 70\text{ mg/dL} < 70 mg/dL in individuals with established atherosclerotic cardiovascular disease); HDL-C > 40 mg/dL \text{HDL-C} > 40\text{ mg/dL} HDL-C > 40 mg/dL in men, > 50 mg/dL > 50\text{ mg/dL} > 50 mg/dL in women; Serum Triglycerides < 150 mg/dL < 150\text{ mg/dL} < 150 mg/dL .
Evidence-Based Macronutrient Allocation
Carbohydrates: 45% to 60% of total energy expenditure. Emphasize low glycemic index (GI), nutrient-dense, fiber-rich sources (legumes, intact whole grains, non-starchy vegetables). Daily dietary fiber intake must achieve 25 to 35 g/day (or 14 g / 1000 kcal 14\text{ g / } 1000\text{ kcal} 14 g / 1000 kcal ), with ≥ 10 g \ge 10\text{ g} ≥ 10 g from soluble viscous fiber.
Protein: 15% to 20% of total energy (approx. 0.8 − 1.0 g/kg/day 0.8 - 1.0\text{ g/kg/day} 0.8 − 1.0 g/kg/day for patients with normal renal function). In established diabetic nephropathy (microalbuminuria or reduced GFR), protein should be maintained at 0.8 g/kg/day 0.8\text{ g/kg/day} 0.8 g/kg/day to reduce glomerular hyperfiltration; excess protein ( > 20 % > 20\% > 20% of total calories) increases renal solute load.
Fats: 20% to 35% of total energy. Saturated fatty acids must be restricted to < 7 % < 7\% < 7% of total calories, trans fatty acids eliminated, and dietary cholesterol limited to < 200 mg/day < 200\text{ mg/day} < 200 mg/day . Replace saturated fats with monounsaturated fatty acids (MUFA, e.g., olive oil, canola oil, avocado) and polyunsaturated fatty acids (PUFA).
Meal Planning Tools: The FNRI Food Exchange Lists for Filipinos
In the Philippines, dietary prescription and meal planning standardly utilize the Food Exchange Lists for Meal Planning published by the Food and Nutrition Research Institute (FNRI-DOST) . In this system, foods are clustered into seven exchange groups such that foods within the same list supply approximately identical quantities of carbohydrate, protein, fat, and energy:
Food Exchange List Carbohydrate (g) Protein (g) Fat (g) Energy (kcal) Standard Portion Examples
Vegetable List A Negligible in small amounts Negligible 0 0 Raw up to 2 cups; pechay, kangkong, mustard greens, cucumber, lettuce
Vegetable List B 3 1 0 16 1/2 cup cooked or 1 cup raw; squash, carrots, sayote, bitter gourd (ampalaya), string beans
Fruit List 10 0 0 40 1 small banana (latundan), 1 slice papaya ( 100 g 100\text{ g} 100 g ), 1 small mango ( 60 g 60\text{ g} 60 g ), 1 medium apple
Rice: Low-Protein 23 0 0 92 Sago, gulaman, tapioca, cornstarch, cassava starch ( 1 / 2 cup cooked 1/2\text{ cup cooked} 1/2 cup cooked )
Rice: Medium-Protein (Standard) 23 2 0 100 1 / 2 cup 1/2\text{ cup} 1/2 cup cooked rice, 1 slice pan de sal ( 25 g 25\text{ g} 25 g ), 1 slice loaf bread, 1 / 2 cup 1/2\text{ cup} 1/2 cup cooked noodles
Rice: High-Protein 23 4 0 108 Whole cooked sweet corn ( 1 / 2 cup 1/2\text{ cup} 1/2 cup ), cooked oatmeal ( 1 / 2 cup 1/2\text{ cup} 1/2 cup )
Milk: Whole 12 8 10 170 1 glass fresh cow's milk ( 240 mL 240\text{ mL} 240 mL ), 4 tbsp whole powdered milk
Milk: Low-Fat 12 8 5 125 1 glass evaporated milk reconstituted 1:1, low-fat liquid milk ( 240 mL 240\text{ mL} 240 mL )
Milk: Skim / Non-Fat 12 8 Trace 80 1 glass skim milk ( 240 mL 240\text{ mL} 240 mL ), 4 tbsp non-fat dry milk powder
Meat: Low-Fat 0 8 1 41 1 matchbox-size lean beef/pork ( 30 g 30\text{ g} 30 g ), chicken breast without skin, galunggong, bangus
Meat: Medium-Fat 0 8 6 86 1 matchbox pork chop, chicken with skin, 1 whole chicken egg ( 50 g 50\text{ g} 50 g ), bangus belly
Meat: High-Fat 0 8 10 122 1 matchbox pork belly (liempo), processed longganisa, canned corned beef, cheddar cheese ( 30 g 30\text{ g} 30 g )
- Fat List 0 0 5 45 1 teaspoon vegetable oil, coconut oil, butter, margarine, mayonnaise
- Sugar List 5 0 0 20 1 level teaspoon white/brown sugar, honey, jam, sweetened syrup
Note
When calculating total caloric distribution for Filipino clients, the standard medium-protein rice exchange ( 23 g CHO , 2 g PRO , 100 kcal 23\text{ g CHO}, 2\text{ g PRO}, 100\text{ kcal} 23 g CHO , 2 g PRO , 100 kcal ) is universally applied across hospital diet manuals and NDLE board problems unless low-protein or high-protein starches are specifically stated.
Carbohydrate Counting: Basic vs. Advanced Protocols
Carbohydrate counting provides flexible meal planning rooted in the physiological fact that carbohydrate is the primary macronutrient driving postprandial blood glucose excursions:
1. Basic Carbohydrate Counting
1 Carbohydrate Choice / Serving = 15 g 15\text{ g} 15 g of Carbohydrate .
Targets are expressed as choices per meal: adult women typically require 3 to 4 carbohydrate choices (45 to 60 g) per meal; adult men require 4 to 5 choices (60 to 75 g) per meal, with 1 to 2 choices (15 to 30 g) for planned snacks.
2. Advanced Carbohydrate Counting (Basal-Bolus Insulin Regimens)
Advanced carbohydrate counting coordinates precise rapid-acting insulin boluses (insulin lispro, aspart, or glulisine) with the grams of carbohydrate ingested, utilizing two critical mathematical algorithms:
A. Insulin-to-Carbohydrate Ratio (ICR) — The 500 Rule
The ICR defines the number of grams of carbohydrate covered by 1 unit of rapid-acting insulin: ICR (g CHO / unit insulin) = 500 Total Daily Dose (TDD) of Insulin \text{ICR (g CHO / unit insulin)} = \frac{500}{\text{Total Daily Dose (TDD) of Insulin}} ICR (g CHO / unit insulin) = Total Daily Dose (TDD) of Insulin 500
Meal Bolus (units) = Grams of Carbohydrate Consumed ICR \text{Meal Bolus (units)} = \frac{\text{Grams of Carbohydrate Consumed}}{\text{ICR}} Meal Bolus (units) = ICR Grams of Carbohydrate Consumed
B. Insulin Sensitivity Factor (ISF) / Correction Factor — The 1800 Rule
The ISF quantifies the anticipated drop in blood glucose (in mg/dL \text{mg/dL} mg/dL ) produced by 1 unit of rapid-acting insulin: ISF (mg/dL / unit insulin) = 1800 Total Daily Dose (TDD) of Insulin \text{ISF (mg/dL / unit insulin)} = \frac{1800}{\text{Total Daily Dose (TDD) of Insulin}} ISF (mg/dL / unit insulin) = Total Daily Dose (TDD) of Insulin 1800 (Note: For regular soluble human insulin, the 1500 Rule is used: ISF = 1500 / TDD \text{ISF} = 1500 / \text{TDD} ISF = 1500/ TDD .)
Correction Bolus (units) = Current Blood Glucose − Target Blood Glucose ISF \text{Correction Bolus (units)} = \frac{\text{Current Blood Glucose} - \text{Target Blood Glucose}}{\text{ISF}} Correction Bolus (units) = ISF Current Blood Glucose − Target Blood Glucose
Total Mealtime Insulin Dose = Meal Bolus + Correction Bolus \text{Total Mealtime Insulin Dose} = \text{Meal Bolus} + \text{Correction Bolus} Total Mealtime Insulin Dose = Meal Bolus + Correction Bolus
Clinical Board Calculation Example
Clinical Scenario: A 32-year-old male with T1DM has a Total Daily Dose (TDD) of 60 units of rapid-acting insulin. His pre-lunch blood glucose is 230 mg/dL 230\text{ mg/dL} 230 mg/dL , his target glucose is 110 mg/dL 110\text{ mg/dL} 110 mg/dL , and he is eating a lunch containing 75 g 75\text{ g} 75 g of carbohydrate.
Calculate ICR: ICR = 500 / 60 = 8.33 g CHO/unit ≈ 8.3 g/unit \text{ICR} = 500 / 60 = 8.33\text{ g CHO/unit} \approx 8.3\text{ g/unit} ICR = 500/60 = 8.33 g CHO/unit ≈ 8.3 g/unit .
Calculate Meal Bolus: 75 / 8.33 = 9.0 units 75 / 8.33 = 9.0\text{ units} 75/8.33 = 9.0 units .
Calculate ISF: ISF = 1800 / 60 = 30 mg/dL per unit \text{ISF} = 1800 / 60 = 30\text{ mg/dL per unit} ISF = 1800/60 = 30 mg/dL per unit .
Calculate Correction Bolus: ( 230 − 110 ) / 30 = 120 / 30 = 4.0 units (230 - 110) / 30 = 120 / 30 = 4.0\text{ units} ( 230 − 110 ) /30 = 120/30 = 4.0 units .
Calculate Total Lunch Bolus: 9.0 + 4.0 = 13.0 units 9.0 + 4.0 = 13.0\text{ units} 9.0 + 4.0 = 13.0 units of rapid-acting insulin.
- Hypoglycemia Management and Nocturnal Glycemic Phenomena
- Hypoglycemia Management: The "Rule of 15"
Hypoglycemia is defined as a blood glucose concentration < 70 mg/dL < 70\text{ mg/dL} < 70 mg/dL ( < 3.9 mmol/L < 3.9\text{ mmol/L} < 3.9 mmol/L ):
Ingest 15 g 15\text{ g} 15 g of fast-acting simple carbohydrate (e.g., 1 / 2 cup 1/2\text{ cup} 1/2 cup [ 120 mL 120\text{ mL} 120 mL ] fruit juice or regular soda, 3 to 4 commercial glucose tablets, 1 tablespoon [ 15 g 15\text{ g} 15 g ] white table sugar dissolved in water, or 1 tablespoon honey).
Wait 15 minutes while resting quietly.
Recheck capillary blood glucose .
If blood glucose remains < 70 mg/dL < 70\text{ mg/dL} < 70 mg/dL , repeat administration of 15 g 15\text{ g} 15 g fast-acting carbohydrate and recheck in 15 minutes.
Once blood glucose normalizes ( ≥ 70 mg/dL \ge 70\text{ mg/dL} ≥ 70 mg/dL ), if the next scheduled meal is > 1 hour > 1\text{ hour} > 1 hour away, the patient must consume a snack containing complex carbohydrate and protein (e.g., crackers with cheese, bread with peanut butter) to sustain euglycemia.
Caution
Avoid treating hypoglycemia with high-fat sweets such as chocolate bars, pastries, or whole milk. The high lipid content substantially delays gastric emptying via cholecystokinin release, blunting the rapid glucose elevation needed to prevent neuroglycopenia and seizure.
Dawn Phenomenon vs. Somogyi Effect
Patients presenting with severe fasting morning hyperglycemia ( > 200 mg/dL > 200\text{ mg/dL} > 200 mg/dL ) require definitive differential diagnosis via a 3:00 AM blood glucose check :
Clinical Parameter Dawn Phenomenon Somogyi Effect (Rebound Hyperglycemia)
3:00 AM Blood Glucose Normal or Elevated ( 90 − 140 + mg/dL 90 - 140+\text{ mg/dL} 90 − 140 + mg/dL ) Hypoglycemic ( < 70 mg/dL < 70\text{ mg/dL} < 70 mg/dL , often < 55 mg/dL < 55\text{ mg/dL} < 55 mg/dL )
Underlying Mechanism Physiological circadian surge of counter-regulatory hormones (growth hormone, cortisol, glucagon, epinephrine) between 4:00 AM and 8:00 AM, accelerating hepatic gluconeogenesis and glycogenolysis. Nocturnal hypoglycemia triggers a massive sympathetic and adrenocortical surge, causing rebound morning hyperglycemia accompanied by night sweats, nightmares, and morning headache.
Dietary & Insulin Intervention Increase evening basal insulin dose , adjust timing of NPH from dinnertime to bedtime, or avoid high-carbohydrate late-night bedtime snacks. Decrease evening basal/intermediate insulin dose , or provide a bedtime snack containing complex carbohydrates and protein (e.g., whole-grain bread with cheese) to prevent nocturnal dipping.
- Medical Nutrition Therapy for Endocrine Disorders
- 1. Hypothyroidism (Hashimoto's Thyroiditis / Post-Ablative)
Metabolic Profile: Substantially depressed Basal Metabolic Rate (BMR decreased by 20% to 40%) leading to hypothermia, fatigue, fluid retention (myxedema), dyslipidemia (impaired LDL receptor clearance), and constipation.
MNT Guidelines: Prescribe a nutrient-dense, calorie-controlled diet to prevent excess weight gain; provide generous dietary fiber (25 to 35 g/day) and fluids (2.0 to 2.5 L/day) to manage constipation; ensure adequate iodine (via iodized salt under RA 8172) and selenium (co-factor for iodothyronine deiodinases converting T 4 T_4 T 4 to active T 3 T_3 T 3 ).
Crucial Drug-Nutrient Interaction: Synthetic levothyroxine ( T 4 T_4 T 4 ) must be taken on an empty stomach with plain water at least 30 to 60 minutes before breakfast . It must be strictly separated by at least 4 hours from calcium carbonate supplements, iron salts, soy protein formulas, and high-fiber supplements, which form insoluble chelates and abolish drug absorption.
2. Hyperthyroidism (Graves' Disease / Toxic Multinodular Goiter)
Metabolic Profile: Marked hypermetabolism (BMR elevated by 50% to 100%), severe somatic protein breakdown, muscle wasting, tremors, tachycardia, osteoporosis due to osteoclastic bone resorption, and polyphagia with rapid weight loss.
MNT Guidelines: High-energy diet ( 35 − 40 kcal/kg/day 35 - 40\text{ kcal/kg/day} 35 − 40 kcal/kg/day , often requiring 3,000 to 4,000 kcal/day); high-protein intake ( 1.5 − 2.0 g/kg/day 1.5 - 2.0\text{ g/kg/day} 1.5 − 2.0 g/kg/day ) to restore somatic nitrogen stores; frequent nutrient-dense meals and between-meal snacks; generous calcium (1,200 to 1,500 mg/day) and Vitamin D supplementation to protect bone mineral density; complete elimination of caffeine and stimulants that exacerbate tachycardia.
3. Polycystic Ovary Syndrome (PCOS)
Metabolic Profile: Hyperandrogenism, chronic anovulation, and polycystic ovarian morphology tightly linked to peripheral insulin resistance (present in 50% to 70% of lean and obese women) and compensatory hyperinsulinemia. Hyperinsulinemia stimulates ovarian theca cell androgen production and suppresses hepatic sex hormone-binding globulin (SHBG) synthesis, worsening clinical hirsutism and central adiposity.
MNT Guidelines:
Modest weight loss of 5% to 10% of baseline body weight significantly restores ovulatory cycles and improves insulin sensitivity.
Anti-inflammatory, low glycemic index / low glycemic load dietary pattern (Mediterranean-style diet).
Balanced macronutrient distribution: Moderate complex carbohydrates (40% to 45% of energy), high fiber ( > 25 g/day > 25\text{ g/day} > 25 g/day ), lean protein (20% to 25%), and healthy fats rich in omega-3 fatty acids and MUFA (30% to 35%) to reduce visceral adiposity.
Targeted supplementation with myo-inositol (2 to 4 g/day) and d-chiro-inositol (40:1 physiological ratio) functions as a secondary messenger for insulin signaling, improving ovulatory function and metabolic markers.